Metformin

What it is

Metformin is an oral biguanide diabetes medicine, first approved in 1994, that lowers blood glucose mainly by reducing liver glucose production. It is widely used as a first-line drug for type 2 diabetes because it usually does not cause weight gain and, when used alone, has a low risk of hypoglycemia. Brand names include Glucophage and, in India, products such as Glycomet. It is available as immediate-release and extended-release tablets, and it is also sold in fixed-dose combinations with other diabetes medicines.

A quick comparison:

Form	Typical use	Key point
Immediate-release	Once to multiple times daily, depending on prescription	More often linked with stomach side effects early on
Extended-release	Usually once daily	May be easier to tolerate for some people

Metformin is used mainly for type 2 diabetes. In some settings it is also used for prediabetes, gestational diabetes, and polycystic ovary syndrome, although not every use is formally approved in every country. In India, metformin is commonly included in diabetes treatment plans alongside diet, exercise, and monitoring of HbA1c, kidney function, and other cardiometabolic risks.

How it works

Metformin lowers blood glucose through several linked effects rather than one single mechanism. The best-established action is a reduction in hepatic gluconeogenesis, meaning the liver makes less new glucose. This helps lower fasting blood sugar.

It also improves insulin sensitivity, especially in the liver and to some extent in peripheral tissues, so the body uses insulin more effectively. Research also suggests effects on the intestine, including altered glucose handling in the gut and changes in gut hormones and the microbiome. At the cellular level, metformin influences energy metabolism and is associated with activation of AMP-activated protein kinase, or AMPK, although AMPK does not explain every clinical effect.

What metformin usually does not do is directly stimulate the pancreas to release more insulin. That is one reason metformin alone has a lower risk of causing low blood sugar than sulfonylureas or insulin.

Evidence and uses

Metformin has the strongest evidence for treatment of type 2 diabetes. Professional guidelines have long placed it among the standard first medicines for many adults with type 2 diabetes, especially when lifestyle changes alone are not enough. It lowers HbA1c by a clinically meaningful amount in many patients, though the exact reduction varies by starting HbA1c, dose, adherence, kidney function, and whether other drugs are used.

Common evidence-based uses include:

1. Type 2 diabetes: Main established use. It improves glycemic control and is often combined with diet, exercise, and other glucose-lowering drugs.
2. Prediabetes: Some guidelines support metformin for selected high-risk people, such as those with obesity, younger age, or prior gestational diabetes, when lifestyle measures are not enough.
3. Polycystic ovary syndrome (PCOS): It may improve insulin resistance and menstrual regularity in some patients, but treatment plans vary depending on fertility goals and symptoms.
4. Gestational diabetes: It is used in some cases, but practice differs by clinician and country, and insulin may still be preferred in many situations.

Metformin has also been studied for possible benefits in cancer, aging, fatty liver disease, and cardiovascular or neuroprotective outcomes. These areas are still being researched. Evidence from observational studies can look promising, but that does not prove cause and effect. Metformin should not be used for anti-aging or cancer prevention outside appropriate clinical guidance.

Safety and interactions

The most common side effects are gastrointestinal. These include nausea, diarrhea, abdominal discomfort, bloating, and reduced appetite, especially when treatment starts or the dose is increased. Taking it with food and using a slow dose escalation can improve tolerance. Extended-release forms may also help some people.

A rare but serious adverse effect is lactic acidosis. The absolute risk is low, but the risk rises in settings where metformin can accumulate or lactate clearance is impaired. Important risk situations include significant kidney dysfunction, severe liver disease, heavy alcohol use, severe infection, dehydration, shock, or low-oxygen states such as severe heart or respiratory failure.

Kidney function matters because metformin is cleared by the kidneys. Current practice generally uses estimated glomerular filtration rate, or eGFR, rather than serum creatinine alone to decide whether metformin can be started or continued. Dose reduction or avoidance may be needed at lower eGFR levels, and kidney function should be checked periodically.

Long-term metformin use can lower vitamin B12 levels in some people. This can contribute to anemia or nerve symptoms such as numbness or tingling. Clinicians may check B12, especially if a person has anemia, neuropathy, or long duration of therapy.

Important practical cautions:

Issue	Why it matters
Reduced kidney function	Can increase metformin accumulation and adverse-effect risk
Iodinated contrast studies	Metformin may need to be held around some imaging procedures, depending on kidney function and clinical context
Alcohol excess	Raises risk of lactic acidosis
Other glucose-lowering drugs	Combination therapy can increase hypoglycemia risk, even though metformin alone rarely does
Vitamin B12 depletion	Can appear with long-term use

Talk to a clinician or pharmacist before combining metformin with prescription drugs, over-the-counter medicines, or supplements. Do not stop or restart it around scans, surgery, vomiting, or severe illness without medical advice.

When to see a clinician

See a clinician promptly if you have persistent vomiting, severe diarrhea, dehydration, unusual sleepiness, fast breathing, severe weakness, or worsening confusion while taking metformin. These can have many causes, but they need assessment.

Also seek review if blood sugars remain high despite treatment, if you develop symptoms of low B12 such as fatigue or tingling in the feet, or if you have a major change in kidney function. People who are pregnant, planning pregnancy, or have chronic kidney disease should use metformin only with individualized medical guidance.

Limitations and open questions

Metformin is effective, inexpensive, and well studied, but it is not the right drug for every person with diabetes. Some people cannot tolerate the gastrointestinal side effects, and others need additional medicines because metformin alone does not achieve target glucose control.

There are also limits to what is known. Its exact mechanism is still not fully settled, despite decades of use. Evidence for non-diabetes uses such as longevity, cancer prevention, and neuroprotection remains incomplete, and human trial results are mixed or still emerging. Even in established uses, benefits and risks depend on kidney function, age, comorbidities, and the rest of the treatment plan.

Metformin should be used as part of a broader diabetes strategy that includes nutrition, physical activity, sleep, cardiovascular risk reduction, and regular follow-up. For readers in India and elsewhere, the safest approach is to use it under a qualified clinician's supervision with periodic checks of HbA1c, kidney function, and, when appropriate, vitamin B12.